Form 4: Harmony Biosciences Holdings Exec Budur Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Chief Medical Officer Kumar Budur of Harmony Biosciences Holdings received stock options and restricted stock units on May 1, 2024, according to a recent SEC filing.
Summary
- Kumar Budur, Chief Medical Officer of Harmony Biosciences Holdings, received stock options for 75,000 shares and 75,000 restricted stock units on May 1, 2024.
- The stock options vest 25% on May 1, 2025, and the remainder vests ratably on a quarterly basis until the fourth anniversary of the grant date.
- The restricted stock units vest in four equal annual installments beginning on May 1, 2025.
- Each restricted stock unit represents a contingent right to receive one share of Harmony Biosciences Holdings' Common Stock.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it incentivizes management.
Positives
- The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
- The vesting schedules incentivize continued service and contribution to the company's success.
Future Outlook
The vesting schedules for both the stock options and restricted stock units suggest a long-term commitment from the executive to the company.
Industry Context
Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.
Comparison to Industry Standards
- Executive compensation packages, including stock options and restricted stock units, are common in the pharmaceutical and biotechnology industries.
- Companies like Jazz Pharmaceuticals and Biohaven Pharmaceutical also utilize similar equity-based compensation to incentivize their executives.
- The vesting schedules are fairly standard, aligning with typical industry practices for retaining key personnel.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align management's interests with the company's long-term performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 05/01/2024 | Date of transaction: grant of stock options and restricted stock units. |
| 05/01/2025 | First vesting date for 25% of the stock options and the first annual installment of the restricted stock units. |
| 05/01/2034 | Expiration date of the stock options. |
| 05/03/2024 | Date of filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.